PTRF/cavin-1 is essential for multidrug resistance in cancer cells

Journal of Proteome Research

Volumn 12, Issue 2, 2013, Pages 605-614

  Yi, Jae Sung ^a   Mun, Dong Gi ^a   Lee, Hyun ^a   Park, Jun Sub ^a   Lee, Jung Woo ^a   Lee, Jae Seon ^b   Kim, Su Jin ^a   Cho, Bong Rae ^a   Lee, Sang Won ^a   Ko, Young Gyu ^a  

^a Korea University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

cavin 1; label free quantitative proteomics; lipid rafts; multidrug resistance; PTRF

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CLAUDIN 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; PROTEIN ZO1; PROTEIN ZO2; UNCLASSIFIED DRUG; VIMENTIN;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MEMBRANE FLUIDITY; CELL STRAIN MCF 7; CELL SURFACE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; LIPID RAFT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARRIER PROTEINS; CAVEOLAE; CAVEOLIN 1; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE MICRODOMAINS; P-GLYCOPROTEIN; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84873371589     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300651m     Document Type: Article

References (63)

1. Baguley, B. C. Multiple drug resistance mechanisms in cancer Mol. Biotechnol. 2010, 46 (3) 308-316
2. Fodale, V.; Pierobon, M.; Liotta, L.; Petricoin, E. Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J. 2011, 17 (2) 89-95
3. Bellamy, W. T. P-glycoproteins and multidrug resistance Annu. Rev. Pharmacol. Toxicol. 1996, 36, 161-183
4. Kimura, Y.; Morita, S. Y.; Matsuo, M.; Ueda, K. Mechanism of multidrug recognition by MDR1/ABCB1 Cancer Sci. 2007, 98 (9) 1303-1310
5. Rumpold, H.; Wolf, A. M.; Gruenewald, K.; Gastl, G.; Gunsilius, E.; Wolf, D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines Exp. Hematol. 2005, 33 (7) 767-775
6. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 1994, 77 (4) 491-502
7. Xing, H.; Wang, S.; Weng, D.; Chen, G.; Yang, X.; Zhou, J.; Xu, G.; Lu, Y.; Ma, D. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids Oncol. Rep. 2007, 17 (1) 117-122
8. Dickstein, B.; Valverius, E. M.; Wosikowski, K.; Saceda, M.; Pearson, J. W.; Martin, M. B.; Bates, S. E. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line J. Cell Physiol. 1993, 157 (1) 110-118
9. Gusterson, B. A.; Gelber, R. D.; Goldhirsch, A.; Price, K. N.; Save-Soderborgh, J.; Anbazhagan, R.; Styles, J.; Rudenstam, C. M.; Golouh, R.; Reed, R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J. Clin. Oncol. 1992, 10 (7) 1049-1056
10. Vickers, P. J.; Dickson, R. B.; Shoemaker, R.; Cowan, K. H. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo Mol. Endocrinol. 1988, 2 (10) 886-892
11. Jones, H. E.; Goddard, L.; Gee, J. M.; Hiscox, S.; Rubini, M.; Barrow, D.; Knowlden, J. M.; Williams, S.; Wakeling, A. E.; Nicholson, R. I. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer 2004, 11 (4) 793-814
12. Lasagna, N.; Fantappie, O.; Solazzo, M.; Morbidelli, L.; Marchetti, S.; Cipriani, G.; Ziche, M.; Mazzanti, R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines Cancer Res. 2006, 66 (5) 2673-2682
13. Kim, B. W.; Lee, C. S.; Yi, J. S.; Lee, J. H.; Lee, J. W.; Choo, H. J.; Jung, S. Y.; Kim, M. S.; Lee, S. W.; Lee, M. S.; Yoon, G.; Ko, Y. G. Lipid raft proteome reveals that oxidative phosphorylation system is associated with the plasma membrane Expert Rev. Proteomics 2010, 7 (6) 849-66
14. Lajoie, P.; Nabi, I. R. Lipid rafts, caveolae, and their endocytosis Int. Rev. Cell. Mol. Biol. 2010, 282, 135-163
15. Helms, J. B.; Zurzolo, C. Lipids as targeting signals: Lipid rafts and intracellular trafficking Traffic 2004, 5 (4) 247-254
16. Hehlgans, S.; Cordes, N. Caveolin-1: An essential modulator of cancer cell radio-and chemoresistance Am. J. Cancer Res. 2011, 1 (4) 521-530
17. Shatz, M.; Liscovitch, M. Caveolin-1: a tumor-promoting role in human cancer Int. J. Radiat. Biol. 2008, 84 (3) 177-189
18. Williams, T. M.; Lisanti, M. P. Caveolin-1 in oncogenic transformation, cancer, and metastasis Am. J. Physiol. Cell Physiol. 2005, 288 (3) C494-506
19. Hansen, C. G.; Nichols, B. J. Exploring the caves: cavins, caveolins and caveolae Trends Cell Biol. 2010, 20 (4) 177-186
20. Capozza, F.; Combs, T. P.; Cohen, A. W.; Cho, Y. R.; Park, S. Y.; Schubert, W.; Williams, T. M.; Brasaemle, D. L.; Jelicks, L. A.; Scherer, P. E.; Kim, J. K.; Lisanti, M. P. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle Am. J. Physiol. Cell Physiol. 2005, 288 (6) C1317-1331
21. Cohen, A. W.; Razani, B.; Wang, X. B.; Combs, T. P.; Williams, T. M.; Scherer, P. E.; Lisanti, M. P. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue Am. J. Physiol. Cell Physiol. 2003, 285 (1) C222-235
22. Hayashi, Y. K.; Matsuda, C.; Ogawa, M.; Goto, K.; Tominaga, K.; Mitsuhashi, S.; Park, Y. E.; Nonaka, I.; Hino-Fukuyo, N.; Haginoya, K.; Sugano, H.; Nishino, I. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy J. Clin. Invest. 2009, 119 (9) 2623-2633
23. Liu, L.; Brown, D.; McKee, M.; Lebrasseur, N. K.; Yang, D.; Albrecht, K. H.; Ravid, K.; Pilch, P. F. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance Cell Metab. 2008, 8 (4) 310-317
24. Volonte, D.; Peoples, A. J.; Galbiati, F. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: Implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C Mol. Biol. Cell 2003, 14 (10) 4075-4088
25. Belanger, M. M.; Gaudreau, M.; Roussel, E.; Couet, J. Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells Cancer Biol. Ther. 2004, 3 (10) 954-959
26. Lavie, Y.; Fiucci, G.; Liscovitch, M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells J. Biol. Chem. 1998, 273 (49) 32380-32383
27. Cai, C.; Zhu, H.; Chen, J. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox Biochem. Biophys. Res. Commun. 2004, 320 (3) 868-874
28. Garrigues, A.; Escargueil, A. E.; Orlowski, S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (16) 10347-10352
29. Troost, J.; Lindenmaier, H.; Haefeli, W. E.; Weiss, J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells Mol. Pharmacol. 2004, 66 (5) 1332-1339
30. Gupta, N.; Wollscheid, B.; Watts, J. D.; Scheer, B.; Aebersold, R.; DeFranco, A. L. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics Nat. Immunol. 2006, 7 (6) 625-633
31. Hill, M. M.; Bastiani, M.; Luetterforst, R.; Kirkham, M.; Kirkham, A.; Nixon, S. J.; Walser, P.; Abankwa, D.; Oorschot, V. M.; Martin, S.; Hancock, J. F.; Parton, R. G. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function Cell 2008, 132 (1) 113-124
32. Kim, K. B.; Kim, B. W.; Choo, H. J.; Kwon, Y. C.; Ahn, B. Y.; Choi, J. S.; Lee, J. S.; Ko, Y. G. Proteome analysis of adipocyte lipid rafts reveals that gC1qR plays essential roles in adipogenesis and insulin signal transduction Proteomics 2009, 9 (9) 2373-2382
33. Lee, C. S.; Yi, J. S.; Jung, S. Y.; Kim, B. W.; Lee, N. R.; Choo, H. J.; Jang, S. Y.; Han, J.; Chi, S. G.; Park, M.; Lee, J. H.; Ko, Y. G. TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1 Cell Death Differ. 2010, 17 (8) 1254-1265
34. Neilson, K. A.; Ali, N. A.; Muralidharan, S.; Mirzaei, M.; Mariani, M.; Assadourian, G.; Lee, A.; van Sluyter, S. C.; Haynes, P. A. Less label, more free: Approaches in label-free quantitative mass spectrometry Proteomics 2011, 11 (4) 535-553
35. Chuthapisith, S.; Layfield, R.; Kerr, I. D.; Hughes, C.; Eremin, O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs Int. J. Oncol. 2007, 30 (6) 1545-1551
36. Gehrmann, M. L.; Fenselau, C.; Hathout, Y. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line J. Proteome Res. 2004, 3 (3) 403-409
37. Gehrmann, M. L.; Hathout, Y.; Fenselau, C. Evaluation of metabolic labeling for comparative proteomics in breast cancer cells J. Proteome Res. 2004, 3 (5) 1063-1068
38. Hathout, Y.; Gehrmann, M. L.; Chertov, A.; Fenselau, C. Proteomic phenotyping: Metastatic and invasive breast cancer Cancer Lett. 2004, 210 (2) 245-253
39. Zhang, F.; Zhang, L.; Zhang, B.; Wei, X.; Yang, Y.; Qi, R. Z.; Ying, G.; Zhang, N.; Niu, R. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells J. Proteome Res. 2009, 8 (11) 5041-5047
40. Lavie, Y.; Liscovitch, M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences Glycoconj. J. 2000, 17 (3 -4) 253-259
41. Lim, C. S.; Kim, H. J.; Lee, J. H.; Tian, Y. S.; Kim, C. H.; Kim, H. M.; Joo, T.; Cho, B. R. A two-photon turn-on probe for lipid rafts with minimum internalization Chembiochem 2010, 12 (3) 392-395
42. Hoffmann, C.; Berking, A.; Agerer, F.; Buntru, A.; Neske, F.; Chhatwal, G. S.; Ohlsen, K.; Hauck, C. R. Caveolin limits membrane microdomain mobility and integrin-mediated uptake of fibronectin-binding pathogens J. Cell Sci. 2010, 123 (Pt 24) 4280-4291
43. Yi, J. S.; Lee, J. Y.; Chi, S. G.; Kim, J. H.; Park, S. G.; Kim, S.; Ko, Y. G. Aminoacyl-tRNA synthetase-interacting multi-functional protein, p43, is imported to endothelial cells via lipid rafts J. Cell Biochem. 2005, 96 (6) 1286-1295
44. Hinrichs, J. W.; Klappe, K.; Hummel, I.; Kok, J. W. ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells J. Biol. Chem. 2004, 279 (7) 5734-5738
45. Zhang, J. T.; Liu, Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment Cancer Treat. Rev. 2007, 33 (8) 741-756
46. Lee, J. M.; Dedhar, S.; Kalluri, R.; Thompson, E. W. The epithelial-mesenchymal transition: New insights in signaling, development, and disease J. Cell Biol. 2006, 172 (7) 973-981
47. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression Nat. Rev. Cancer 2002, 2 (6) 442-454
48. Thiery, J. P.; Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions Nat. Rev. Mol. Cell. Biol. 2006, 7 (2) 131-142
49. Kajiyama, H.; Shibata, K.; Terauchi, M.; Yamashita, M.; Ino, K.; Nawa, A.; Kikkawa, F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells Int. J. Oncol. 2007, 31 (2) 277-283
50. Li, Q. Q.; Xu, J. D.; Wang, W. J.; Cao, X. X.; Chen, Q.; Tang, F.; Chen, Z. Q.; Liu, X. P.; Xu, Z. D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells Clin. Cancer Res. 2009, 15 (8) 2657-2665
51. Iseri, O. D.; Kars, M. D.; Arpaci, F.; Atalay, C.; Pak, I.; Gunduz, U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern Biomed. Pharmacother. 2011, 65 (1) 40-45
52. Yi, J. S.; Choo, H. J.; Cho, B. R.; Kim, H. M.; Kim, Y. N.; Ham, Y. M.; Ko, Y. G. Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption Biochem. Biophys. Res. Commun. 2009, 385 (2) 154-159
53. Wisniewski, J. R.; Zougman, A.; Nagaraj, N.; Mann, M. Universal sample preparation method for proteome analysis Nat Methods 2009, 6 (5) 359-362
54. Hyung, S. W.; Kim, M. S.; Mun, D. G.; Lee, H.; Lee, S. W. The effect and potential of using a temperature controlled separation column with ultra-high pressure microcapillary liquid chromatography/tandem mass spectrometry on proteomic analysis Analyst 2011, 136 (10) 2100-2105
55. Kelly, R. T.; Page, J. S.; Tang, K.; Smith, R. D. Array of chemically etched fused-silica emitters for improving the sensitivity and quantitation of electrospray ionization mass spectrometry Anal. Chem. 2007, 79 (11) 4192-4198
56. Jung, H. J.; Purvine, S. O.; Kim, H.; Petyuk, V. A.; Hyung, S. W.; Monroe, M. E.; Mun, D. G.; Kim, K. C.; Park, J. M.; Kim, S. J.; Tolic, N.; Slysz, G. W.; Moore, R. J.; Zhao, R.; Adkins, J. N.; Anderson, G. A.; Lee, H.; Camp, D. G., 2nd; Yu, M. H.; Smith, R. D.; Lee, S. W. Integrated post-experiment monoisotopic mass refinement: an integrated approach to accurately assign monoisotopic precursor masses to tandem mass spectrometric data Anal. Chem. 2010, 82 (20) 8510-8518
57. Elias, J. E.; Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry Nat. Methods 2007, 4 (3) 207-214
58. Horn, D. M.; Zubarev, R. A.; McLafferty, F. W. Automated reduction and interpretation of high resolution electrospray mass spectra of large molecules J. Am. Soc. Mass Spectrom. 2000, 11 (4) 320-332
59. Hyung, S. W.; Lee, M. Y.; Yu, J. H.; Shin, B.; Jung, H. J.; Park, J. M.; Han, W.; Lee, K. M.; Moon, H. G.; Zhang, H.; Aebersold, R.; Hwang, D.; Lee, S. W.; Yu, M. H.; Noh, D. Y. A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers Mol. Cell. Proteomics 2011, 10 (10) M111 011023
60. Jaitly, N.; Monroe, M. E.; Petyuk, V. A.; Clauss, T. R.; Adkins, J. N.; Smith, R. D. Robust algorithm for alignment of liquid chromatography-mass spectrometry analyses in an accurate mass and time tag data analysis pipeline Anal. Chem. 2006, 78 (21) 7397-7409
61. Callister, S. J.; Barry, R. C.; Adkins, J. N.; Johnson, E. T.; Qian, W. J.; Webb-Robertson, B. J.; Smith, R. D.; Lipton, M. S. Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics J. Proteome Res. 2006, 5 (2) 277-286
62. Zhang, B.; Chambers, M. C.; Tabb, D. L. Proteomic parsimony through bipartite graph analysis improves accuracy and transparency J. Proteome Res. 2007, 6 (9) 3549-3457
63. Carrillo, B.; Yanofsky, C.; Laboissiere, S.; Nadon, R.; Kearney, R. E. Methods for combining peptide intensities to estimate relative protein abundance Bioinformatics 2010, 26 (1) 98-103